Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri.

Abstract

Treatment with acetazolamide for pseudotumor cerebri (PTC) in a renal transplant patient led to an acute, but reversible deterioration in renal function. Possible pathogenetic mechanisms behind acute renal failure and acetazolamide are detailed. In summary, caution should be exercised in all patients with chronic renal failure who require acetazolamide. It should be avoided if possible, used in reduced doses when necessary, and coupled with a high fluid intake to avoid dehydration and/or intraluminal obstruction.

• Authors: A Korzets, U Gafter, S Floru, A Chagnac, D Zevin
• Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 21 Issue 3 Pg. 322-4 (Mar 1993) ISSN: 0272-6386 [Print] United States
• PMID: 8447311 (Publication Type: Case Reports, Journal Article)

Chemical References

• Acetazolamide

Topics

• Acetazolamide (adverse effects, therapeutic use)
• Acute Kidney Injury (chemically induced)
• Adult
• Female
• Humans
• Kidney Transplantation (physiology)
• Pseudotumor Cerebri (drug therapy)